Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer

E. A. de Bruijn, A. T. van Oosterom, U. R. Tjaden, H. J. Reeuwijk, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

The pharmacokinetics of the new fluoropyrimidine 5'-deoxy-5-fluorouridine (5'-dFUrd) was investigated in twelve patients. The kinetics of the main metabolite 5-fluorouracil (5-FUra) was studied in eight patients and those of 5,6-dihydro-5-fluorouracil (5-FUraH2) in five patients. The patients participated in a Phase II study performed to investigate the response rate of 5'-dFUrd in advanced ovarian cancer. The pharmacokinetic data were compared with the clinical effects of the drug. The parent drug and 5-FUra were measured in both plasma and urine by high performance liquid chromatography. 5-FUraH2 concentrations in plasma were determined by capillary gas chromatography using electron capture detection and nitrogen-phosphorus specific detection. Several pharmacokinetic parameters such as elimination half-life, mean residence time, and steady state volumes of distribution are presented for 5'-dFUrd, 5-FUra, and 5-FUraH2. Two patients showed a partial response, four had stable disease, and five had progressive disease; one patient died due to myelotoxicity. The severity of the side effects correlated with the mean residence times of 5'-dFUrd and 5-FUra. Low pretreatment serum creatinine clearance (due to renal impairment) correlated with low renal excretion of 5'-dFUrd and a long mean residence time of 5'-dFUrd with the sum of observed toxicity. However, the extent of degradation of 5-FUra to 5-FUraH2 may also be related to the severity of the toxicity of 5'-dFUrd.

Original languageEnglish (US)
Pages (from-to)5931-5935
Number of pages5
JournalCancer Research
Volume45
Issue number11 II
StatePublished - 1985
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Fluorouracil
Pharmacology
Pharmacokinetics
doxifluridine
Pharmaceutical Preparations
Gas Chromatography
Phosphorus
Half-Life
Creatinine
Nitrogen
Parents
High Pressure Liquid Chromatography
Urine
Electrons
Kidney
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

de Bruijn, E. A., van Oosterom, A. T., Tjaden, U. R., Reeuwijk, H. J., & Pinedo, H. M. (1985). Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer. Cancer Research, 45(11 II), 5931-5935.

Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer. / de Bruijn, E. A.; van Oosterom, A. T.; Tjaden, U. R.; Reeuwijk, H. J.; Pinedo, H. M.

In: Cancer Research, Vol. 45, No. 11 II, 1985, p. 5931-5935.

Research output: Contribution to journalArticle

de Bruijn, EA, van Oosterom, AT, Tjaden, UR, Reeuwijk, HJ & Pinedo, HM 1985, 'Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer', Cancer Research, vol. 45, no. 11 II, pp. 5931-5935.
de Bruijn EA, van Oosterom AT, Tjaden UR, Reeuwijk HJ, Pinedo HM. Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer. Cancer Research. 1985;45(11 II):5931-5935.
de Bruijn, E. A. ; van Oosterom, A. T. ; Tjaden, U. R. ; Reeuwijk, H. J. ; Pinedo, H. M. / Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer. In: Cancer Research. 1985 ; Vol. 45, No. 11 II. pp. 5931-5935.
@article{98b2f11e2eb14e4e9a80092074e3511f,
title = "Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer",
abstract = "The pharmacokinetics of the new fluoropyrimidine 5'-deoxy-5-fluorouridine (5'-dFUrd) was investigated in twelve patients. The kinetics of the main metabolite 5-fluorouracil (5-FUra) was studied in eight patients and those of 5,6-dihydro-5-fluorouracil (5-FUraH2) in five patients. The patients participated in a Phase II study performed to investigate the response rate of 5'-dFUrd in advanced ovarian cancer. The pharmacokinetic data were compared with the clinical effects of the drug. The parent drug and 5-FUra were measured in both plasma and urine by high performance liquid chromatography. 5-FUraH2 concentrations in plasma were determined by capillary gas chromatography using electron capture detection and nitrogen-phosphorus specific detection. Several pharmacokinetic parameters such as elimination half-life, mean residence time, and steady state volumes of distribution are presented for 5'-dFUrd, 5-FUra, and 5-FUraH2. Two patients showed a partial response, four had stable disease, and five had progressive disease; one patient died due to myelotoxicity. The severity of the side effects correlated with the mean residence times of 5'-dFUrd and 5-FUra. Low pretreatment serum creatinine clearance (due to renal impairment) correlated with low renal excretion of 5'-dFUrd and a long mean residence time of 5'-dFUrd with the sum of observed toxicity. However, the extent of degradation of 5-FUra to 5-FUraH2 may also be related to the severity of the toxicity of 5'-dFUrd.",
author = "{de Bruijn}, {E. A.} and {van Oosterom}, {A. T.} and Tjaden, {U. R.} and Reeuwijk, {H. J.} and Pinedo, {H. M.}",
year = "1985",
language = "English (US)",
volume = "45",
pages = "5931--5935",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "11 II",

}

TY - JOUR

T1 - Pharmacology of 5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer

AU - de Bruijn, E. A.

AU - van Oosterom, A. T.

AU - Tjaden, U. R.

AU - Reeuwijk, H. J.

AU - Pinedo, H. M.

PY - 1985

Y1 - 1985

N2 - The pharmacokinetics of the new fluoropyrimidine 5'-deoxy-5-fluorouridine (5'-dFUrd) was investigated in twelve patients. The kinetics of the main metabolite 5-fluorouracil (5-FUra) was studied in eight patients and those of 5,6-dihydro-5-fluorouracil (5-FUraH2) in five patients. The patients participated in a Phase II study performed to investigate the response rate of 5'-dFUrd in advanced ovarian cancer. The pharmacokinetic data were compared with the clinical effects of the drug. The parent drug and 5-FUra were measured in both plasma and urine by high performance liquid chromatography. 5-FUraH2 concentrations in plasma were determined by capillary gas chromatography using electron capture detection and nitrogen-phosphorus specific detection. Several pharmacokinetic parameters such as elimination half-life, mean residence time, and steady state volumes of distribution are presented for 5'-dFUrd, 5-FUra, and 5-FUraH2. Two patients showed a partial response, four had stable disease, and five had progressive disease; one patient died due to myelotoxicity. The severity of the side effects correlated with the mean residence times of 5'-dFUrd and 5-FUra. Low pretreatment serum creatinine clearance (due to renal impairment) correlated with low renal excretion of 5'-dFUrd and a long mean residence time of 5'-dFUrd with the sum of observed toxicity. However, the extent of degradation of 5-FUra to 5-FUraH2 may also be related to the severity of the toxicity of 5'-dFUrd.

AB - The pharmacokinetics of the new fluoropyrimidine 5'-deoxy-5-fluorouridine (5'-dFUrd) was investigated in twelve patients. The kinetics of the main metabolite 5-fluorouracil (5-FUra) was studied in eight patients and those of 5,6-dihydro-5-fluorouracil (5-FUraH2) in five patients. The patients participated in a Phase II study performed to investigate the response rate of 5'-dFUrd in advanced ovarian cancer. The pharmacokinetic data were compared with the clinical effects of the drug. The parent drug and 5-FUra were measured in both plasma and urine by high performance liquid chromatography. 5-FUraH2 concentrations in plasma were determined by capillary gas chromatography using electron capture detection and nitrogen-phosphorus specific detection. Several pharmacokinetic parameters such as elimination half-life, mean residence time, and steady state volumes of distribution are presented for 5'-dFUrd, 5-FUra, and 5-FUraH2. Two patients showed a partial response, four had stable disease, and five had progressive disease; one patient died due to myelotoxicity. The severity of the side effects correlated with the mean residence times of 5'-dFUrd and 5-FUra. Low pretreatment serum creatinine clearance (due to renal impairment) correlated with low renal excretion of 5'-dFUrd and a long mean residence time of 5'-dFUrd with the sum of observed toxicity. However, the extent of degradation of 5-FUra to 5-FUraH2 may also be related to the severity of the toxicity of 5'-dFUrd.

UR - http://www.scopus.com/inward/record.url?scp=0022366257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022366257&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 5931

EP - 5935

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 11 II

ER -